First Trust Nasdaq Pharmaceuticals ETF

FTXH

Capitalización de mercado USD 1077 M

The First Trust NASDAQ Pharmaceuticals ETF (FTXH) was launched on 09/20/2016, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the First Trust NASDAQ Pharmaceuticals ETF (FTXH), a passively managed exchange traded fund launched on September 20, 2016.

The First Trust NASDAQ Pharmaceuticals ETF (FTXH) was launched on 09/20/2016, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the First Trust NASDAQ Pharmaceuticals ETF (FTXH) is a passively managed exchange traded fund launched on September 20, 2016.

U.S. President Donald Trump will ‌announce a dramatic expansion of TrumpRx.gov, a government-backed website offering discounted prescription drugs under his ​administration's pricing deal, on Monday, a White ​House official said.

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.

On Thursday, news broke that the US will likely start levying a 100% tariff on branded pharmaceutical imports. The specifics remain unclear, but the levy is expected to be relatively narrow in scope, since many exemptions have already been negotiated.

Europe's pharmaceutical industry needs to make sure it doesn't become yesterday's news. Its biopharmaceutical innovation capacity has been gradually declining for decades, and the rapid ascent of China and President Trump's policies risk accelerating that decay.

Pharma ETF FTXH hits a new 52-week high as industry momentum, rate cuts, and AI adoption lift the sector???signaling potential near-term upside for FTXH investors.